Novartis Pharmaceuticals Corporation. Data on file. GILENYA exposure: May 2018 cutoff. East Hanover, NJ: Novartis Pharmaceuticals Corporation, 2018.
2.
CohenJABarkhofFComiG, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med2010; 362: 402–415.
3.
CarpenterAFGoodwinSJBornsteinPF, et al. Cutaneous cryptococcosis in a patient taking fingolimod for multiple sclerosis: Here come the opportunistic infections. Mult Scler2017; 23(2): 297–299.
4.
BergerJRCreeBAGreenbergB, et al. Progressive multifocal leukoencephalopathy after fingolimod treatment. Neurology2018; 90(20): e1815–e1821.
5.
ArtemiadisAKNikolaouGKolokythopoulosD, et al. Visceral leishmaniasis infection in a fingolimod-treated multiple sclerosis patient. Mult Scler2015; 21(6): 795–796.
6.
TriplettJKermodeAGCorbettA, et al. Warts and all: Fingolimod and unusual HPV-associated lesions. Mult Scler2019; 25: 1547–1550.
7.
JaafarNZeineddineMMassouhJ, et al. Skin warts during fingolimod treatment in patients with multiple sclerosis. In: 34th congress of the European Committee for treatment and research in multiple sclerosis, Berlin, 10–12 October 2018.
8.
BenedettiMDMarangiABozzettiS, et al. HPV-related papillary squamous cell carcinoma of the tonsil during treatment with fingolimod. Mult Scler Relat Disord2018; 23: 24–26.
9.
CornellSDiguilioEStockmanK, et al. Does fingolimod increase the risk of developing human papillomavirus (HPV) related cancers: A case series. In: Annual meeting of the consortium of multiple sclerosis centers, New Orleans, LA, 24–27 May 2017.
10.
Soelberg SorensenP. Safety concerns and risk management of multiple sclerosis therapies. Acta Neurol Scand2017; 136(3): 168–186.
11.
LublinFMillerDHFreedmanMS, et al. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): A phase 3, randomised, double-blind, placebo-controlled trial. Lancet2016; 387: 1075–1084.
12.
KillesteinJLeursCEHoogervorstELJ, et al. Five cases of malignant melanoma during fingolimod treatment in Dutch patients with MS. Neurology2017; 89(9): 970–972.
